COMMUNIQUÉS West-GlobeNewswire

Seer Announces CFO Transition
21/09/2026
REDWOOD CITY, Calif., Sept. 21, 2026 (GLOBE NEWSWIRE) -- Seer, Inc. (Nasdaq: SEER) (“Seer” or the “Company”), the pioneer and trusted partner for deep, unbiased proteomic insights, today announced that David Horn, the [...]
Axsome Therapeutics Announces Results of the Shared Goals Survey of Caregivers of Patients with Alzheimer’s Disease Agitation Presented at Psych Congress 2026 in Connection with World Alzheimer’s Day
21/09/2026
The Shared Goals: Navigating Alzheimer’s Agitation survey finds that Alzheimer’s disease agitation is often only recognized after daily life is significantly disrupted Ninety-seven percent of care partners reported that [...]
Tiziana Announces Last Patient Completes Last Visit in Phase 2a INFORM-MS Trial of Intranasal Foralumab
21/09/2026
BOSTON, Sept. 21, 2026 (GLOBE NEWSWIRE) -- Tiziana Life Sciences, Ltd. (Nasdaq: TLSA ) (“Tiziana” or the “Company”), a biotechnology company developing breakthrough immunomodulation therapies with its lead development [...]
Underarm Pad Surface Area and Handle Angle: The Measurements Behind Crutch Comfort
21/09/2026
Drive Medical builds the MD by Drive Air-Crutch handle angle and grip size around load calculations run at the handgrip by Max Younger, who designed the crutch and now leads the line. The Airgonomic™ underarm cushion [...]
Novo's CagriSema delivers superior weight loss versus tirzepatide in REIMAGINE 5 trial
21/09/2026
CagriSema 1.0 mg/1.0 mg achieved superior weight loss of 12.4%* versus tirzepatide 5 mg of 9.1%* and non-inferior HbA 1c reduction at week 60 in adults with type 2 diabetes in REIMAGINE 5. CagriSema 1.0 mg/1.0 mg [...]
ALK appoints Tina Abild Olesen as Executive Vice President for Corporate, Portfolio and Product Strategy
21/09/2026
ALK today announced the appointment of Tina Abild Olesen as Executive Vice President for Corporate, Portfolio and Product Strategy (CPPS), effective 1 October 2026. Tina succeeds Jacob Glenting, who headed CPPS before [...]
Highlights to be presented at Novo’s Capital Markets Day 2026
21/09/2026
Bagsværd, Denmark, 21 September 2026 – Novo Nordisk is today hosting a Capital Markets Day (CMD) in London, where the company is providing an update to its Corporate strategy and strategic ambitions for 2030 1 . During [...]
Bavarian Nordic – Transactions in Connection with Share Buy-Back Program
21/09/2026
COPENHAGEN, Denmark, September 21, 2026 – Bavarian Nordic A/S (OMX: BAVA) announces transactions under the share buy-back program launched on September 1, 2026, under which the Company will repurchase shares for an [...]
Beacon Therapeutics Reports Positive Topline Data from the Pivotal VISTA Trial of Laru-zova for the Treatment of X-linked Retinitis Pigmentosa (XLRP)
21/09/2026
VISTA met its FDA-endorsed primary endpoint, demonstrating statistically significant low luminance visual acuity (LLVA) responder rates at Month 12 compared to the untreated control group A statistically significant [...]
Telix and ITM Join Forces to Create a Radiopharmaceutical Powerhouse
21/09/2026
Transformational merger reinforces Telix’s long-term growth strategy as a vertically integrated radiopharmaceutical company with enhanced capabilities across development, isotope production and global manufacturing, [...]
SodaPeak Launch 2026: Effective Formula For Men Health Supports Men's Virility and vitality. Read Soda Peak Gummies Supplement Facts & Ingredients Highlights.
20/09/2026
Soda Peak Gummies introduces a natural vitality formula for men, featuring SodaPeak with selected botanical ingredients, supplement facts, and a multi-ingredient blend designed for everyday men’s wellness and vitality [...]
Cue Biopharma Announces Positive Topline Results from CUE-221 Phase 2 Study in Chronic Spontaneous Urticaria
20/09/2026
Results support potential for differentiated clinical impact for patients suffering from chronic hives and advancement to Phase 2b/3 registration enabling study Primary endpoint and the key secondary endpoint were met [...]
NorahLux Launches Red Light Therapy Research Hub With Access to 10,000+ Photobiomodulation Studies
20/09/2026
Interactive research explorer helps users search scientific literature by condition, study type, light source and other criteria DEURNE, Netherlands, Sept. 19, 2026 (GLOBE NEWSWIRE) -- NorahLux has launched the Red [...]
Iovance Biotherapeutics Reports Inducement Grants under NASDAQ Listing Rule 5635(c)(4)
18/09/2026
SAN CARLOS, Calif., Sept. 18, 2026 (GLOBE NEWSWIRE) -- Iovance Biotherapeutics, Inc. (NASDAQ: IOVA) ("Iovance" or the “Company”), a biotechnology company focused on innovating, developing, and delivering novel [...]
Johns Hopkins USFHP is One of the Highest-Rated Health Plans in the Nation
18/09/2026
TRICARE Prime® Option Earns 4.5/5 in NCQA’s 2026 Ratings HANOVER, Md., Sept. 18, 2026 (GLOBE NEWSWIRE) -- Johns Hopkins US Family Health Plan (USFHP) was recognized with an overall rating of 4.5 out of 5 in the National [...]
New Teva Study Identifies the Attributes that Healthcare Providers Prioritize when Selecting a Treatment for Tardive Dyskinesia in Older Patients
18/09/2026
New data revealed that healthcare providers prioritize drowsiness risk, duration of available data demonstrating long-term response and drug-drug interaction profile when selecting a treatment for tardive dyskinesia (TD [...]
Teva Highlights New Real-World Data Showing UZEDY® (risperidone) Outperforms Other Long-Acting Injectables in Keeping Schizophrenia Patients on Treatment, While Reducing Emergency Care and Healthcare Costs
18/09/2026
New findings show favorable treatment continuity for UZEDY compared to other long-acting injectables in schizophrenia, as well as oral antipsychotics in bipolar I disorder (BD-I) The new real-world data also show that [...]
Teva Announces New Olanzapine LAI (TEV-'749) Post Hoc Data Highlighting High Rates of Stabilization and Long-Term Efficacy as Once-Monthly Subcutaneous Injectable for the Treatment of Schizophrenia in Adults
18/09/2026
In a post hoc analysis of the open-label safety stage of the Phase 3 SOLARIS trial, more than half of participants receiving TEV-'749 achieved stabilization, few relapsed and more than one-fifth of participants [...]
NurExone Expands U.S. Engagement Across Four Major Boston Life Sciences Events and Provides Corporate Update
18/09/2026
CEO Dr. Lior Shaltiel and R&D Director Dr. Tali Kizhner to engage with industry, investors and scientific leaders during a concentrated week in Boston TORONTO and HAIFA, Israel, Sept. 18, 2026 (GLOBE NEWSWIRE) -- [...]

Pages